The recent review of some of the major projects in this industry sector demonstrates the positive impact of strategic ...

In October, lenacapavir manufacturer, Gilead, announced a deal that allows six manufacturers to produce generic versions of ...

The stock's fall snapped an eight-day winning streak.

It’s been called the closest the world has ever come to a vaccine against the AIDS virus. The twice-yearly shot was 100% ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

The sixth and final season of The Handmaid's Tale is in production for Hulu and promises to wrap up one of the most acclaimed ...

US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...